Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/7900
INDOMETHACIN TREATMENT SLOWS DISEASE PROGRESSION AND ENHANCES A TH1 RESPONSE IN SUSCEPTIBLE BALB/C MICE INFECTED WITH LEISHMANIA MAJOR.
Indometacina/uso terapêutico
Leishmania major
Leishmaniose Cutânea/quimioterapia
Células Th1/imunologia
Animais
Inibidores de Ciclo-Oxigenase/uso terapêutico
Progressão da Doença
Feminino
Imunidade Celular
Leishmaniose Cutânea/imunologia
Camundongos
Camundongos Endogâmicos BALB C
Antagonistas de Prostaglandina/uso terapêutico
Author
Affilliation
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório de Patologia e Biologia Celular. Salvador, BA, Brasil
Colorado State University. Department of Pathology. College of Veterinary Medicine and Biomedical Sciences. Fort Collins, USA
Colorado State University. Department of Pathology. College of Veterinary Medicine and Biomedical Sciences. Fort Collins, USA
Colorado State University. Department of Pathology. College of Veterinary Medicine and Biomedical Sciences. Fort Collins, USA
Colorado State University. Department of Pathology. College of Veterinary Medicine and Biomedical Sciences. Fort Collins, USA
Colorado State University. Department of Pathology. College of Veterinary Medicine and Biomedical Sciences. Fort Collins, USA
Colorado State University. Department of Pathology. College of Veterinary Medicine and Biomedical Sciences. Fort Collins, USA
Colorado State University. Department of Pathology. College of Veterinary Medicine and Biomedical Sciences. Fort Collins, USA
Colorado State University. Department of Pathology. College of Veterinary Medicine and Biomedical Sciences. Fort Collins, USA
Abstract
Prostaglandins of the E series inhibit the development of Th1 responses. When infected with Leishmania major, BALB/c mice fail to develop a Th1 response, but instead mount a Th2 response and die of the disease. Therefore, we treated L. major-infected BALB/c mice with indomethacin, which inhibits prostaglandin production. Indomethacin lessened disease severity (parasite burden and pathology), and promoted a Th1 response, but the mice still succumbed to infection. The explanation for these observations may be two-fold: (1) the beneficial effects of indomethacin were predominantly observed later in infection (beyond two weeks), a time at which indomethacin was unable to sufficiently block the development of a Th2 response; (2) indomethacin was unable to induce a Th1 response in BALB/c mice that was of the same magnitude as the Th1 response observed in C57BL/6 mice infected with L. major.
DeCS
Antiprotozoários/uso terapêuticoIndometacina/uso terapêutico
Leishmania major
Leishmaniose Cutânea/quimioterapia
Células Th1/imunologia
Animais
Inibidores de Ciclo-Oxigenase/uso terapêutico
Progressão da Doença
Feminino
Imunidade Celular
Leishmaniose Cutânea/imunologia
Camundongos
Camundongos Endogâmicos BALB C
Antagonistas de Prostaglandina/uso terapêutico
Share